Financials data is unavailable for this security.
View more
Year on year Formosa Laboratories Inc had net income fall -69.16% from 409.36m to 126.24m despite revenues that grew 15.80% from 3.77bn to 4.36bn over the same period.
| Gross margin | 44.30% |
|---|---|
| Net profit margin | 2.03% |
| Operating margin | 15.72% |
| Return on assets | 0.71% |
|---|---|
| Return on equity | 3.41% |
| Return on investment | 0.97% |
More ▼
Cash flow in TWDView more
In 2023, Formosa Laboratories Inc increased its cash reserves by 19.27%, or 246.55m. The company earned 826.60m from its operations for a Cash Flow Margin of 18.96%. In addition the company generated 700.14m cash from financing while 1.26bn was spent on investing.
| Cash flow per share | 4.98 |
|---|---|
| Price/Cash flow per share | 19.91 |
| Book value per share | 62.49 |
|---|---|
| Tangible book value per share | 60.62 |
More ▼
Balance sheet in TWDView more
| Current ratio | 1.82 |
|---|---|
| Quick ratio | 1.18 |
| Total debt/total equity | 0.4966 |
|---|---|
| Total debt/total capital | 0.3155 |
More ▼
Growth rates in TWD
Year on year, growth in dividends per share increased 100.00% while earnings per share excluding extraordinary items fell by -69.06%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.33% |
|---|---|
| Div growth rate (5 year) | 32.22% |
| Payout ratio (TTM) | 93.97% |
| EPS growth(5 years) | -9.50 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -70.90 |
More ▼
